Complementary and alternative medicine in European countries—legislative framework
Journal Title: Traditional Medicine Research - Year 2020, Vol 5, Issue 3
Abstract
Complementary and alternative medicine (CAM) is a set of different diagnostic and therapeutic procedures, as well as the use of natural products for the treatment of patients, derived from previously known traditional methods and enriched with modern scientific knowledge. The present article reviews the available data regarding the use of CAM and the legislation behind it in European countries. The use of CAM is recorded in Europe as a whole and varies between 10-70% of the population of individual European countries. At least 300,000 registered CAM providers have been identified in the European Union (EU), of which slightly more than half includes non-medical practitioners. The most practiced discipline is acupuncture, followed by homeopathy. CAM regulation and legislation in Europe is not precisely defined and is constantly striving to find a common approach. Since legal frameworks for CAM are not defined, each European country has its own regulations and legislation. In order to define universal legislation for CAM, the EU created the CAMbrella project, a project of the EU designed to find a unique system that would include the treatment of CAM in Europe. According to the data from CAMbrella, from 39 countries in the EU, 17 have general CAM legislations. The status of CAM in Europe is characterized by enormous heterogeneity in all aspects, including terminology, methods, prevalence and ultimately, legal status, regulations and legislation.
Authors and Affiliations
Jovana Milenkovic, Sergey Bolevich, Gvozden Rosic
Keywords
Related Articles
- EP ID EP680184
- DOI 10.12032/TMR20190718125
- Views 194
- Downloads 0
Nephrotoxicity and carcinogenesis of aristolochic acids and their derivates
Aristolochic acids (AAs), a natural mixture of 8-methoxy-6-nitro-phenanthro-(3,4-d)-1,3-dioxolo-5-carboxylic acid (AAI) and 6-nitro-phenanthro-(3,4-d)-1,3-dioxolo-5-carboxylic acid (AAII), derived from aristolochiaceae s...
Is "Pangolin (Manis Squama) is not used in medicine" an improvement in the protection of precious and rare species or an improvement in the safety of using medicine?
Recently, a number of reports about pangolin have become hot news: The Chinese Pharmacopoeia (2020 edition) has not continued to include the drug-using standards for pangolin (Manis Squama), aristolochic (Aristolochia...
Network pharmacology-based approach to investigate the mechanisms of Yiyi Fuzi Baijiang Powder in the treatment of malignant tumors
Objective: To systematically investigate the main active components, targets, target-related diseases and action mechanism of Yiyi Fuzi Baijiang powder (YFBP) of Zhang Zhongjing, a Chinese physician of Eastern Han Dynast...
India’s indigenous idea of herd immunity: the solution for COVID-19?
Based on folklore and traditional wisdom, when a shepherd purchases a few new sheep from an unknown seller or from a distant place, he keeps them away from his old flock of sheep for a period of 15 days. This, in other w...
Research progress on anti-tumor properties of Marsdenia tenacissima
Tongguanteng (Marsdenia tenacissima), which is mainly distributed in the Yunnan and Guizhou provinces of China, was first recorded in Diannanbencao by Lan Mao of the Ming dynasty of China. According to recent pharmacolog...